| Host: |
Rabbit |
| Applications: |
WB |
| Reactivity: |
Human/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-ARHGAP45 (1-160) is suitable for use in Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:500-1:2000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
ARHGAP45 |
| Gene ID: |
23526 |
| Uniprot ID: |
HMHA1_HUMAN |
| Immunogen Region: |
1-160 |
| Immunogen: |
Recombinant fusion protein containing a sequence corresponding to amino acids 1-160 of human ARHGAP45 (NP_036424.2). |
| Immunogen Sequence: |
MFSRKKRELMKTPSISKKNR AGSPSPQPSGELPRKDGADA VFPGPSLEPPAGSSGVKATG TLKRPTSLSRHASAAGFPLS GAASWTLGRSHRSPLTAASP GELPTEGAGPDVVEDISHLL ADVARFAEGLEKLKECVLRD DLLEARRPRAHECLGEALRV |
| Tissue Specificity | Expressed on cells of the hematopoietic lineage. Detected in dendritic cells and epidermal Langerhans cells. Expressed in peripheral blood mononuclear cells, in all leukemia/lymphoma cell lines. Detected also in some solid tumors and tissues such as cancerous and non-cancerous tissue. |
| Function | Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domin which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL. |
| Protein Name | Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1Mhag Ha-1 |
| Database Links | Reactome: R-HSA-6798695Reactome: R-HSA-8980692Reactome: R-HSA-9013148Reactome: R-HSA-9013149 |
| Cellular Localisation | CytoplasmCell ProjectionRuffle Membrane |
| Alternative Antibody Names | Anti-Rho Gtpase-Activating Protein 45 Cleaved Into - Minor Histocompatibility Antigen Ha-1 antibodyAnti-Mhag Ha-1 antibodyAnti-ARHGAP45 antibodyAnti-HMHA1 antibodyAnti-KIAA0223 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
